Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib extension in SLE
NCT03407482Phase 2Terminated
- Sponsor
- Genentech
- Start
- Jan 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of fenebrutinib in systemic lupus erythematosus (SLE), sponsored by Genentech. Started Jan 2018; status: terminated.
02
Drugs
fenebrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03407482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407482.